Acquisition of Arysta Life Sciences, a part of the US-based Platform Specialty Products, if it goes through will make UPL the world's fifth largest crop protection company and the largest generic player with combined revenues of slightly lower than $4.6 billion. The company is currently the ninth largest with annual revenues of $2.7 billion.
While the company is not commenting on the acquisition reports, if the deal goes through the key benefit according to analysts at Citi Research is the higher scale which will help in distribution both for getting better terms from distributors as well as the ability to